Asia300

PT Kalbe Farma Tbk

Indonesia

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Feb 22, 2018
Prev close: 1,615
Feb 22, 2018
Market cap:
Market cap(USD):
75,703.32B
5,532.85M
Shares: 46,875.12M

Currency in IDR

Company profile

Market(Ticker): JKT(KLBF)
Sector:
Industry:
Health Technology
Pharmaceuticals: Other
Full time employees: --

Business summary

PT Kalbe Farma Tbk engages in the development, production, distribution, and trade of pharmaceutical products. It operates through the following segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical segment offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores throughout Indonesia. The Consumer Health segment provides over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals segment sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistics segment maintains distribution of the company's and third party principal's products across Indonesia, and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.

Company background

Indonesia's Kalbe Farma is one of Southeast Asia's largest pharmaceutical companies. It has a diverse lineup of products, ranging from prescription medicine to vitamins to energy drinks.

The company has its own distribution network that carries products to a large number of retail outlets. It also distributes products for major foreign pharmaceutical companies, including Astellas Pharma of Japan and Baxter of the U.S.

Kalbe Farma was launched out of a garage by Boenjamin Setiawan, who is now in his 80s, and his brothers. Setiawan has left the board of directors and now serves as honorary chairman. His niece, Bernadette Ruth Irawati Setiady, has served as president since 2008. The group of founders holds a significant stake in the company.

Kalbe Farma has been expanding its consumer sector, acquiring local health-drink producer Hale International in 2012. The company exports some of its products to neighboring countries.

In the news

Financial highlights

Dec 2017

  • Local currency
  • US Dollar
Revenue 20,199B
Gross profit --
Operating income 3,197B
Income before tax 3,234B
Net income 2,381B
EBITDA --
Diluted EPS --
Dividends per share --
Total assets --
Total liabilities --
Total equity --
Operating cash flow --

Currency in IDR

Revenue 1,509.43M
Gross profit --
Operating income 238.90M
Income before tax 241.67M
Net income 177.92M
EBITDA --
Diluted EPS --
Dividends per share --
Total assets --
Total liabilities --
Total equity --
Operating cash flow --

Currency in USD

Valuation measures

Dec 2017

PER 33.27
ROA --
ROE --
Operating margin 15.82%
Profit margin 11.78%

Key executive

  • President Director: Bernadette Ruth Setiady
  • Head-Corporate Finance, Accounting & Tax: Bernadus Karmin Winata
  • Head-Corporate Information Technology & System: Dino Bramanto
  • Director: Bujung Nugroho
  • Director: Ongkie Tedjasurja

Share holders

  • SWAN KHOUW LIP(10.1%)
  • SETIAWAN BOENJAMIN(9.6%)
  • VERONICA GERDA(9.5%)
  • KARMILA MARIA(9.4%)
  • HARSHINI THERESIA(9.2%)
  • ARYANTO FRANCISCUS BING(8.6%)
  • First State Investment Management (UK) Ltd.(1.7%)
  • The Vanguard Group, Inc.(1.3%)
  • BlackRock Fund Advisors(1.3%)
  • PT Schroder Investment Management Indonesia(0.9%)

Address

  • Website: http://www.kalbe.co.id
  • Address: Gedung KALBE, Jalan Let. Jend. Suprapto Kavling 4, Jakarta, 10510, Indonesia
  • Phone: +62.21.4287.3888

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.